McKesson Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for McKesson Corporation for the quarter ended June 30, 2005 (Fiscal Year 2006, Q1). McKesson operates as a leading healthcare services company with three primary segments: Pharmaceutical Solutions, Medical-Surgical Solutions, and Provider Technologies. The company's fiscal year runs from April 1 to March 31.
Key Financial Metrics
| Metric | Q1 2006 (Jun 30, 2005) | Q1 2005 (Jun 30, 2004) |
|---|---|---|
| Revenues | $21,058 million | $19,175 million |
| Gross Profit | $925 million | $849 million |
| Gross Margin | 4.39% | 4.43% |
| Operating Income | $261 million | $260 million |
| Net Income | $171 million | $164 million |
| Diluted EPS | $0.55 | $0.55 |
| Cash from Operations | $637 million | $111 million |
| Cash and Equivalents | $2,409 million | $837 million |
| Long-Term Debt | $992 million | $1,202 million |
| Working Capital | $3,936 million | $3,570 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 10% year-over-year, driven primarily by the Pharmaceutical Solutions segment (95% of total revenue), which saw growth in U.S. direct distribution and Canadian operations.
- Operating Expenses: Total operating expenses rose 13% to $664 million. This increase was largely due to a $52 million pre-tax charge related to Securities Litigation reserves. Excluding this charge, operating expenses increased only 4%.
- Cash Flow: Net cash provided by operating activities surged to $637 million from $111 million in the prior year. This improvement was driven by better working capital management (specifically inventory and accounts payable alignment) and a $143 million cash receipt from an amended contract with the UK's National Health Services (NHS).
- Debt Reduction: Long-term debt decreased by approximately $210 million, reflecting the repayment of term debt and the exchange of convertible debentures for common stock.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted strong revenue growth and improved operating cash flow. However, they noted that net income was reduced by an after-tax Securities Litigation charge of $35 million ($0.11 per diluted share). The company expects to meet future cash requirements, including litigation settlements, through existing cash balances and operating cash flows.
Acquisitions and Divestitures:
- Acquisitions: Agreements were announced to acquire D&K Healthcare Resources (approx. $207 million) and Medcon, Ltd. (approx. $105 million), expected to close in Q2 2006.
- Divestiture: An agreement was reached to sell McKesson BioServices for approximately $62 million, with results reported as discontinued operations.
Risks and Contingencies:
- Securities Litigation: The company maintains a $1,221 million accrual for the resolution of securities litigation regarding the 1999 HBOC accounting restatement. While management believes the reserve is adequate, they warn that ultimate costs could exceed this amount, potentially having a material adverse impact.
- Forward-Looking Risks: Risks include the changing U.S. healthcare environment, consolidation of competitors, manufacturer pricing changes, and the outcome of pending litigation.
Investor Verification Checklist
- Litigation Reserve Adequacy: Verify the sufficiency of the $1.221 billion accrual for securities litigation and monitor for any new settlements or court rulings that could increase this liability.
- Working Capital Trends: Confirm the sustainability of the improved working capital cycle, specifically the reduction in net financial inventory, as this significantly boosted operating cash flow.
- Margin Pressure: Monitor the Pharmaceutical Solutions segment's gross margin, which declined slightly (9 basis points) due to reduced manufacturer compensation seasonality and new institutional customer agreements.
- Acquisition Integration: Track the closing and integration of the D&K and Medcon acquisitions scheduled for the second quarter of 2006.
- Stock Repurchases: Note the company's active share repurchase program ($66 million spent in the quarter) and its impact on diluted share count.